The effect of vitamin C and E in the treatment and clinical course of patients with SARS-cov2 (COVID-19)

INTERVENTION: Intervention 1: Intervention group: Includes 40 patients with COVID‐19 for 5 days, hydroxychloroquine sulfate tablets with lopinavir / ritonavir tablets of 200/50 mg, 2 tablets every 12 hours, or 400 mg hydroxychloroquine diet on the first day and then 200 mg. It will be given every 12 hours. In addition to the above, 1 gram of oral vitamin C and 400 units of oral vitamin E will be prescribed daily during the patient's hospital stay. Intervention 2: Control group: Includes 40 patients with COVID‐19 for 5 days, hydroxychloroquine sulfate tablets with lopinavir / ritonavir tablets of 200/50 mg, 2 tablets every 12 hours, or 400 mg hydroxychloroquine diet on the first day and then 200 mg. It will be given every 12 hours. CONDITION: SARS‐cov2(COVID‐19). ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: Clinical response. Timepoint: During hospitalizatio. Method of measurement: Cessation of fever, improvement of shortness of breath, reduction of cough, blood oxygenation (SaO2) and hemodynamic parameters. Hospital stay. Timepoint: During hospitalizatio. Method of measurement: Count the number of hospital days to improve clinical symptoms. Mortality. Timepoint: During hospitalizatio. Method of measurement: Count the number of dead patients. INCLUSION CRITERIA: 18 years of age or older Diagnosis of COVID‐19 by RT PCR and CT scan of the lungs Blood oxygen levels are between 90 and 93 percent Breathing rate between 20 and 24 per minute Heart rate between 100 and 130 beats per minute